Chao Rong

Dr. Chao Rong

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MZMeng Zhang
Meng Zhang
CRChao Rong
Chao Rong
JWJia-Jian Wang
Jia-Jian Wang
ZXZi-Han Xu
Zi-Han Xu
JZJihong Zhang
Jihong Zhang
Xian-Wen YangXian-Wen Yang
Xian-Wen Yang
Seven new (1–7) and six known (8–13) statin derivatives were obtained from the deep-sea-derived fungus Penicillium viridicatum MCCC 3A00265. The structures assigned to the new compounds were based on a comprehensive analysis of the spectroscopic data, with absolute configurations established by Mosher analysis and biogenetic consideration. Most of the new compounds (1–5 and 7) share an octohydronaphthalene backbone, except that viridecalin F (6) possesses an uncommon naphthalene core. Viridecalins C (3) and F (6) and the two known compounds 9 and 11 exhibit considerable ability in reactivating mutant p53 protein at 10 μM, while viridecalin C showcases the most potent reactivation activity, indicating the potential of application in cancer therapy.

23 March 2026 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ZLZeQing Li
ZeQing Li
LCLei Chen
Lei Chen
YWYuan Wang
Yuan Wang
MJMengjiao Jiang
Mengjiao Jiang
SFSiyu Fang
Siyu Fang
ZHZhong Tian hua
Zhong Tian hua
Five previously undescribed steroids, chrysogenones A–E (1–5), were isolated from the deep-sea-derived Penicillium sp. MCCC 3A00121. Their chemical structures were unambiguously established through comprehensive spectroscopic analyses, density functional theory (DFT)-based electronic circular dichroism (ECD) calculations, and X-ray crystallography. Chrysogenones represent a class of oxidatively modified ergosterone-type derivatives, with 1, 2, and 5 featuring an uncommon malonyl substitution at C-12 of the ergosterone skeleton. Biologically, 1–5 exhibited varying degrees of inhibitory activity against renal fibrosis, as evidenced by the downregulation of the key fibrotic markers α-smooth muscle actin (α-SMA) and collagen I (COL1A1). Among them, chrysogenone B (2) emerged as the most promising candidate, demonstrating superior potency and pronounced inhibition of activated NRK-49F cell proliferation. Integrated network pharmacology analysis and molecular docking studies further suggested that the anti-renal fibrotic effects of compound 2 may be mediated through its interaction with putative molecular targets, including AKT1, HSP90AA1, and MDM2.